Sterile Injectables CDMO Market Report 2026

The sterile injectables cdmo market size has grown rapidly in recent years. It will grow from $6.65 billion in 2025 to $7.36 billion in 2026 at a compound annual growth rate (CAGR) of 10.7%. The growth in the historic period can be attributed to limited cdmo infrastructure for sterile injectables, growing demand for small molecule injectables, reliance on in-house formulation development, increasing regulatory scrutiny for sterile manufacturing, rising global pharmaceutical production.

The sterile injectables cdmo market size is expected to see rapid growth in the next few years. It will grow to $10.91 billion in 2030 at a compound annual growth rate (CAGR) of 10.3%. The growth in the forecast period can be attributed to expansion of large molecule biologics manufacturing, increasing demand for cell and gene therapies, adoption of advanced aseptic processing technologies, rising outsourcing to cdmos, growth in specialized packaging and cold chain storage requirements. Major trends in the forecast period include rising demand for contract manufacturing of sterile injectables, expansion of analytical and testing services for quality assurance, growth in monoclonal antibodies, peptides, and cell/gene therapy production, increasing adoption of lyophilized, emulsion, and reconstitutable injectable formats, integration of formulation development with packaging and storage solutions.

The increasing demand for biologics and biosimilars is expected to drive the growth of the sterile injectables CDMO market in the coming years. Biologics are therapies derived from living cells or organisms that target specific disease mechanisms, while biosimilars are highly similar versions of approved biologics, matching them in quality, safety, and efficacy. The rising need for biologics and biosimilars is fueled by the growing incidence of chronic and complex health conditions, as these therapies offer more targeted and effective treatments than conventional drugs. This demand increases reliance on sterile injectable CDMO services, as such therapies are typically administered via injection and require rigorously controlled sterile environments to maintain safety, quality, and regulatory compliance. For instance, in February 2025, the Center for Biosimilars, a US-based nonprofit research organization, reported that the US spent an estimated $324 billion on biologic medicines in 2023, accounting for roughly 45% of total prescription drug expenditures. Therefore, the rising demand for biologics and biosimilars is propelling the sterile injectables CDMO market.

Key companies in the sterile injectables CDMO market are focusing on advanced technologies, such as modular aseptic filling platforms, to enhance flexibility and efficiency in sterile drug production. Modular aseptic filling platforms are isolator-based sterile filling systems composed of interchangeable modules, allowing CDMOs to switch quickly between vial, syringe, or cartridge formats. This reduces changeover time, minimizes product loss, and efficiently supports small- to mid-scale batches for both clinical and commercial production. For example, in February 2025, Recipharm AB, a Sweden-based CDMO, launched a fully operational modular sterile filling system at its Wasserburg, Germany facility. The system is designed for aseptic filling of batches ranging from 500 to 50,000 units, minimizes product loss to under 500 milliliters, and supports interchangeable modules within a fully enclosed isolator for high-value biologics.

In October 2023, Advent International and Warburg Pincus, US-based private equity firms, acquired Baxter’s BioPharma Solutions business for $4.25 billion. The business was rebranded as Simtra BioPharma Solutions, operating independently as a CDMO offering end-to-end sterile manufacturing, parenteral delivery, and specialized support for pharmaceutical and biotech clients. Baxter International is a US-based provider of sterile injectable CDMO services.

Major companies operating in the sterile injectables cdmo market are Pfizer Inc., Thermo Fisher Scientific Inc., Boehringer Ingelheim, Fresenius Kabi AG, Lonza Group Ltd., Catalent Inc., Samsung Biologics Co. Ltd., Fareva SA, Recipharm AB, PCI Pharma Services, Vetter Pharma, Delpharm, Kindeva Drug Delivery LP, Ajinomoto Bio-Pharma Services, Cenexi, Grand River Aseptic Manufacturing Inc., INCOG BioPharma Services, Aurigene Pharmaceutical Services, Jubilant HollisterStier LLC, Symbiosis Pharmaceutical Services Ltd., Afton Scientific Corp., Amaran Biotechnology Inc.

North America was the largest region in the sterile injectables CDMO market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the sterile injectables cdmo market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the sterile injectables cdmo market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have influenced the sterile injectables CDMO market by increasing costs for imported raw materials, biopharmaceutical ingredients, and advanced manufacturing equipment. Segments like large molecule biologics, vaccines, and monoclonal antibodies are most impacted, particularly in regions like North America and Europe that rely heavily on imports. This has resulted in higher production costs and potential delays in project timelines. On the positive side, tariffs have encouraged local production capabilities, innovation in aseptic technologies, and investment in domestic CDMO infrastructure.

The sterile injectables cdmo market research report is one of a series of new reports that provides sterile injectables cdmo market statistics, including sterile injectables cdmo industry global market size, regional shares, competitors with a sterile injectables cdmo market share, detailed sterile injectables cdmo market segments, market trends and opportunities, and any further data you may need to thrive in the sterile injectables cdmo industry. This sterile injectables cdmo market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Sterile injectables CDMOs are contract development and manufacturing organizations that specialize in producing injectable pharmaceutical products under sterile conditions. These organizations operate in compliance with strict regulatory standards to ensure the safety, efficacy, and quality of their products. They provide critical infrastructure, expertise, and controlled environments necessary for aseptic processing, playing an essential role in the pharmaceutical supply chain.

The main types of sterile injectable CDMOs include small molecule and large molecule products. Small molecules are low molecular weight compounds that can easily enter cells due to their simple chemical structure. These organizations offer services such as formulation development, analytical testing, manufacturing, packaging, and storage. Sterile injectables are administered through various routes, including subcutaneous (SC), intravenous (IV), and intramuscular (IM), and are applied across therapeutic areas such as oncology, cardiovascular diseases, central nervous system disorders, infectious diseases, musculoskeletal disorders, and hormonal diseases. They serve a range of end users, including pharmaceutical companies, biopharmaceutical companies, and research institutes.

The sterile injectables CDMO market consists of revenues earned by entities by providing services such as microbiological testing, sterilization validation, labeling, and regulatory support. The market value includes the value of related goods sold by the service provider or included within the service offering. The sterile injectables CDMO market also includes sales of cartridges, emulsions, infusion bags, and implants. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.